


The following listing of claims replaces all prior versions, and listings, of claims in the application:

IN THE CLAIMS:

1. (Currently amended) A compound of the formula



wherein

x is from 0 to 2;

R¹ is selected from the group consisting of hydroxy, C₁ to C₉ alkoxy (optionally substituted by halo), C₁ to C₉ cycloalkylalkoxy (wherein the cycloalkyl group is optionally substituted by C₁ to C₄ alkyl or halo, and the alkoxy group is optionally substituted by halo), arylalkoxy (wherein the aryl group is optionally substituted by C₁ to C₄ alkyl, C₁ to C₃ alkoxy or halo, and the alkoxy group is optionally substituted by halo) and C₁ to C₉ alkyl amino (wherein the alkyl group is optionally substituted by halo)


R² is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl and cycloalkylalkyl, wherein alkyl moieties are optionally substituted by halo, and aryl groups are optionally substituted by C₁ to C₄ alkyl, C₁ to C₄ alkoxy and halo,

R³ is absent when -Y-Z-R² is attached to N, or R³ is selected from the group consisting of H, C₁ to C₇ alkyl and benzyl, when


-Y-Z-R² is not attached to N;

Y is C₂ to C₁₀ alkylene, in which one non-terminal carbon atom may be replaced by O; and

Z is



wherein R^5 , R^6 and R^7 are independently H, aryl (C_1 to C_3) alkyl or cycloalkyl (C_1 to C_3) alkyl optionally substituted by halo, and Q is H or methyl, or Q is linked to R^5 or R^7 to form a five-membered ring or Q is linked to R^2 to form a six-membered ring, provided that when Z is



at least one of R^5 and R^7 is aryl(C_1 to C_3)alkyl or cycloalkyl(C_1 to C_3)alkyl, optionally substituted by halo;
or a pharmaceutically acceptable salt thereof.